Improved pregnancy outcomes of cyclosporine A on patients with unexplained repeated implantation failure in IVF/ICSI cycles: A retrospective cohort study.

Abstract

Repeated implantation failure (RIF) is a daunting obstacle restricting the further improvement of embryo implantation rate (IR) and live birth rate (LBR). The beneficial effect of cyclosporine A (CsA) on reproductive outcomes of unexplained RIF(URIF) was explored after de novo embryo transfer (ET). A retrospective cohort study was conducted, comparing pregnancy outcomes of 146 cycles (CsA group, n=62; control group, n=84) at the IVF center of Suzhou Municipal Hospital from April 2016 to March 2020. Baseline and transfer cycle characteristics of participants were comparable between groups. Overall, CsA exerted obvious improvement on IR (51.16% vs 31.97%, P=.006), clinical pregnancy rate (CPR) (58.06% vs 38.10%, P=.017), and LBR (48.39% vs 32.14%, P=.047). Especially, CsA showed remarkably enhancement on IR (41.38% vs 14.63%, P=.012), CPR (47.62% vs 17.24%, P=.021) of non-high quality embryos. No difference in obstetric and pediatric complications was observed, and no birth defects were reported under CsA application. CsA was found to be a predictor of clinical pregnancy [fine adjusted OR 2.360, 95 % CI 1.165-4.781; P=.017] and live birth [fine adjusted OR 2.339, 95% CI 1.124-4.867; P=.023] for multivariate logistic regression. Not surprisingly, the number of high quality embryos should also be considered as an independent predictor for clinical pregnancy [fine adjusted OR 1.637,95%CI 1.027-2.609; P=.038] and live birth [fine adjusted OR 1.890, 95% CI 1.165-3.068; P=.010]. CsA application in patients with URIF promotes the pregnancy outcomes and does not increase the risk of obstetric and pediatric complications.